arrow
W

Wenhao Xu

fudan university
H指数:28
被引数:2,965

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical Outcomes, Treatment Patterns, and Molecular Heterogeneity of TFE3-Rearranged Renal Cell Carcinoma: A Multicenter Real-World Study

TFE3易位型肾细胞癌的临床结局、治疗模式及分子异质性:一项多中心真实世界研究

2026-09-150
OAAI
Re: Laurence Albiges, Thomas Powles, Anand Sharma, et al. CaboPoint: A Phase 2 Study of Second-line Cabozantinib After Checkpoint Inhibitor-based Combination Therapy in Patients with Metastatic Renal Cell Carcinoma. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2025.07.018

Re: Laurence Albiges, Thomas Powles, Anand Sharma, et al. CaboPoint:一项在经免疫检查点抑制剂为基础的联合疗法后,对转移性肾细胞癌患者进行二线卡博赞替尼治疗的II期研究。Eur Urol. In press. https://doi.org/10.1016/j.eururo.2025.07.018

2025-12-130
PRE
Polystyrene Microplastics Exposure Aggravates Clear Cell Renal Cell Carcinoma Progression via the NF-κB and TGF-β Signaling Pathways

聚苯乙烯微塑料暴露通过NF-κB和TGF-β信号通路加剧透明细胞肾细胞癌进展

2025-11-270
OAAI
ACOX2 destabilizes the MRE11-RAD50-NBS1 complex and boosts anticancer immunity via the cGAS-STING pathway in clear cell renal cell carcinoma

ACOX2通过cGAS-STING通路破坏MRE11-RAD50-NBS1复合物的稳定性,并增强透明细胞肾细胞癌中的抗肿瘤免疫。

2025-10-230
OAAI
Integrated clinical and proteomic-based model for diagnostic and prognostic prediction in pRCC

基于临床和蛋白质组学的pRCC诊断和预后预测模型

2025-05-280
OA